Literature DB >> 29328000

Conscious sedation with dexmedetomidine compared with asleep-awake-asleep craniotomies in glioma surgery: an analysis of 180 patients.

Eric Suero Molina1, Stephanie Schipmann1, Isabelle Mueller1, Johannes Wölfer1, Christian Ewelt1, Matthias Maas2, Benjamin Brokinkel1, Walter Stummer1.   

Abstract

OBJECTIVEAwake craniotomies have become a feasible tool over time to treat brain tumors located in eloquent regions. Different techniques have been applied in neurooncology centers. Both "asleep-awake-asleep" (asleep) and "conscious sedation" were used subsequently at the authors' neurosurgical department. Since 2013, the authors have only performed conscious sedation surgeries, predominantly using the α2-receptor agonist dexmedetomidine as the anesthetic drug. The aim of this study was to compare both mentioned techniques and evaluate the clinical use of dexmedetomidine in the setting of awake craniotomies for glioma surgery.METHODSThe authors retrospectively analyzed patients who underwent operations either under the asleep condition using propofol-remifentanil or under conscious sedation conditions using dexmedetomidine infusions. In the asleep group patients were intubated with a laryngeal mask and extubated for the assessment period. Adverse events, as well as applied drugs with doses and frequency of usage, were recorded.RESULTSFrom 224 awake surgeries between 2009 and 2015, 180 were performed for the resection of gliomas and included in the study. In the conscious sedation group (n = 75) significantly fewer opiates (p < 0.001) and vasoactive (p < 0.001) and antihypertensive (p < 0.001) drugs were used in comparison with the asleep group (n = 105). Furthermore, the postoperative length of stay (p < 0.001) and the surgical duration (p < 0.001) were significantly lower in the conscious sedation group.CONCLUSIONSUse of dexmedetomidine creates excellent conditions for awake surgeries. It sedates moderately and acts as an anxiolytic. Thus, after ceasing infusion it enables quick and reliable clinical neurological assessment of patients. This might lead to reducing the amount of administered antihypertensive and vasoactive drugs as well as the length of hospitalization, while likely ensuring more rapid surgery.

Entities:  

Keywords:  AA = anaplastic astrocytoma; ASA = American Society of Anesthesiologists; CI = confidence interval; MAP = mean arterial pressure; awake craniotomy; dexmedetomidine; glioma; sedation; surgical technique

Mesh:

Substances:

Year:  2018        PMID: 29328000     DOI: 10.3171/2017.7.JNS171312

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Analysis of Dexmedetomidine on the Quality of Awakening During Neurosurgery.

Authors:  Jing Cao; Hui Li; Shengwen Song; Xuyan Zhou; Xu Shen
Journal:  Transl Neurosci       Date:  2019-07-12       Impact factor: 1.757

2.  Dexmedetomidine Compared to Remifentanil Infusion as Adjuvant to Sevoflurane Anesthesia during Laparoscopic Sleeve Gastrectomy.

Authors:  Jehan M E Hamed; Hesham S M Refaat; Hamed Al-Wadaani
Journal:  Anesth Essays Res       Date:  2019-12-16

3.  5-Aminolevulinic Acid Fluorescence-Guided Resection of 18F-FET-PET Positive Tumor Beyond Gadolinium Enhancing Tumor Improves Survival in Glioblastoma.

Authors:  Michael Müther; Raphael Koch; Matthias Weckesser; Peter Sporns; Wolfram Schwindt; Walter Stummer
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

4.  Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management.

Authors:  Michael Schwake; Michael Müther; Ann-Katrin Bruns; Bastian Zinnhardt; Nils Warneke; Markus Holling; Stephanie Schipmann; Benjamin Brokinkel; Johannes Wölfer; Walter Stummer; Oliver Grauer
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

5.  A novel online calculator predicting short-term postoperative outcomes in patients with metastatic brain tumors.

Authors:  Adham M Khalafallah; Adrian E Jimenez; Palak Patel; Sakibul Huq; Omar Azmeh; Debraj Mukherjee
Journal:  J Neurooncol       Date:  2020-09-22       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.